Ocaratuzumab

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

Retrieved on: 
Monday, June 1, 2020
Medical Supplies, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Viruses, Immunology, Monoclonal antibodies, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Antibody, Coronavirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Ocaratuzumab, LY-CoV555, AbCellera Biologics Inc.

LY-CoV555 is developed from a fully human monoclonal antibody identified from the first blood sample obtained from a North American patient who recovered from COVID-19.

Key Points: 
  • LY-CoV555 is developed from a fully human monoclonal antibody identified from the first blood sample obtained from a North American patient who recovered from COVID-19.
  • LY-CoV555 was developed at record speed, taking less than three months to advance from screen to first-in-human clinical trials.
  • Lilly is independently leading the clinical development and testing of the resulting potential antibody therapeutics.
  • LY-CoV555 is a highly potent, neutralizing IgG1 monoclonal antibody that targets the spike protein of SARS-CoV-2, the novel coronavirus that causes COVID-19.

Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II

Retrieved on: 
Thursday, May 21, 2020
Medical specialties, Monoclonal antibodies, Immunology, Medicine, Branches of biology, Antibody, Humanized antibody, Ocaratuzumab, Monoclonal antibody therapy

SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announcedthat it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences, in a poster during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held from June 22-24.

Key Points: 
  • SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announcedthat it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences, in a poster during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held from June 22-24.
  • The preclinical characterization of TST001, a novel humanized anti-claudin18.2 mAb with enhanced binding affinity and anti-tumor activity.
  • TST001 is a humanized monoclonal antibody targeting human Claudin18 isoform 2 (CLDN18.2).
  • As a humanized monoclonal antibody with high binding affinity to CLDN18.2, TST001 kills tumor cells mainly by antibody-dependent cellular cytotoxicity (ADCC).